Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS

Key Takeaways

• First participant enrolled at Mass General Brigham.
• 500‑patient, 48‑week, randomized 3:2 pridopidine/placebo.
• Targets rapidly progressive ALS within 18 months onset.
• Builds on positive subgroup data from Phase 2 HEALEY trial.
• Pridopidine holds orphan drug status in US/EU.

Summary

Prilenia Therapeutics and Ferrer have enrolled the first participant in PREVAiLS, a pivotal Phase 3, 500‑patient, randomized, placebo‑controlled trial of the sigma‑1 receptor agonist pridopidine for rapidly progressive ALS. The study, launched at Mass General Brigham, will span 48 weeks with a 3:2 active‑to‑placebo ratio and includes an open‑label extension. It builds on a promising subgroup analysis from the Phase 2 HEALEY ALS Platform Trial that suggested benefit in fast‑progressing patients. Enrollment will expand across up to 60 sites in 13 countries, aiming to confirm efficacy and safety in early‑stage disease.

Pulse Analysis

Amyotrophic lateral sclerosis remains one of the most lethal neurodegenerative disorders, with average survival of just two to five years after diagnosis. Conventional therapies offer modest symptomatic relief, leaving a stark gap for disease‑modifying agents. Pridopidine, originally investigated for Huntington’s disease, targets the sigma‑1 receptor—a protein implicated in cellular stress response and neuronal survival. Early data from the HEALEY platform trial hinted that patients with rapid disease progression might derive functional benefits, sparking interest in a more focused evaluation.

The PREVAiLS trial marks a strategic escalation, enrolling 500 participants who are within 18 months of symptom onset and exhibit fast‑progressing ALS. Its primary endpoint—change in ALSFRS‑R adjusted for mortality—directly measures functional decline, while secondary outcomes capture survival, speech, respiratory capacity, and quality‑of‑life metrics. By distributing enrollment across 60 leading centers in North America, Europe, the UK, and Israel, the study ensures diverse patient representation and accelerates recruitment. The 48‑week double‑blind phase followed by an open‑label extension provides a robust safety window, essential for a chronic condition.

From a market perspective, a positive readout could catapult pridopidine into the rare‑disease pipeline as a first‑in‑class sigma‑1 receptor therapy for ALS, complementing existing treatments like riluzole and edaravone. The drug already holds orphan designation in the United States and European Union, positioning it for expedited regulatory pathways should efficacy be demonstrated. Investors and biotech partners are likely to monitor interim data closely, as success would validate the sigma‑1 receptor as a viable therapeutic target across neurodegenerative diseases, potentially unlocking new collaborations and funding streams.